Abstract
Psychotic disorders are serious mental illnesses and they have a fundamental influence on the life of patients. For a proven way to prevent relapse is considered a long-term injectable antipsychotic treatment.
The fundamental scientific findings show that treatment with any antipsychotic drugs is associated with significant prolongation of life expectancy of patients. Aldo adherence to the antipsychotic treatment proves to be the most important factor in the development of the initial stages of relapse in schizophrenia.
One option is to use a longacting injectable second generation antipsychotics, which conceal the benefits of a long-acting injectable form and properties of atypical antipsychotics. In the Czech Republic compared to most European countries use of a long-acting injectable atypical antipsychotic is 2-4 times less.
This divergence of clinical practice deserves attention and further research into therapeutic practice.